Palo Alto Well-Positioned To Drive Strong Growth, Profitability And FCF, Analysts Say
Barclays analyst Saket Kalia maintained Palo Alto Networks Inc (NASDAQ: PANW) with an Overweight and
Gap Faces Holiday Uncertainty Heading Into Q4, Says Analyst
Telsey Advisory Group analyst Dana Telsey reiterated with a Market Perform rating on the shares of Gap Inc (NYSE:GPS) and raised the…
Cowen Thinks Jack In The Box’s Q4 Adj EBITDA To Be Affected By Economic Challenges
Cowen & Co analyst Andrew Charles reiterated a Market Perform rating on the shares of Jack In The Box Inc (NASDAQ:JACK)…
HP Analysts Go Cautious As Macro Concerns Challenge Near-Term Potential
Credit Suisse analyst Shannon Cross downgrades HP Inc (NYSE:HPQ) from Outperform to Neutral with a $33 price target. Cross believes revenue and…
Kulicke & Soffa Analyst Sees No Meaningful Rebound In Near Term; Recommends Moving To The Sidelines
Needham analyst Charles Shi has reiterated a Hold rating on the shares of Kulicke & Soffa Industries Inc (NASDAQ:KLIC). With the company guiding…
3 Applied Materials Analysts On Earnings After Report Triggers A Rally
Applied Materials, Inc's (NASDAQ: AMAT) quarterly earnings triggered a rally.
Mizuho Securities On Applied Materials
These 2 Ross Stores Analysts Raise Price Targets After Q3 Print
Ross Stores, Inc. (NASDAQ: ROST) reported upbeat earnings on Thursday.
Read more about where Ross Stores stands with analysts here.
Why This Alibaba Analyst Is Cutting Price Target After Q2 Results
US Tiger Securities analyst Bo Pei reduced his price target on Alibaba Group Holding Ltd (NYSE: BABA) to $110 from $120, while maintaining a ‘Buy’ rating on the stock, after the company implied gross merchandise value (GMV) could
Lack Of Supply Cuts From Samsung Could Lead To Higher Inventory Build-Up For Micron, Analyst Says
Mizuho analyst Jason Getz reiterated Neutral on Micron Technology, Inc (NASDAQ:MU) with a $52 price target. MU announced further DRAM and NAND…
Analyst Expects ‘Somewhat Smaller Effect Size’ From Gossamer Bio’s Upcoming PAH Trial
Raymond James maintains Outperform on Gossamer Bio Inc (NASDAQ:GOSS) with a price target down from $18 to $15. The analyst expects a…